Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer

Objective: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients withadvanced non-small cell lung cancer (NSCLC). Materials and
Methods: A total of 72 patients were randomlydivided into a combination group (pemetrexed+bevacizumab, n=36) and a pemetrexed group (n=36) and assessedfor disease control (CR+PR+SD) after 4-cycles of first-line GP chemotherapy (gemcitabine+cisplatin). Clinicalefficacy, progression-free survival time (PFS), overall survival time (OS), overall response rate (ORR), diseasecontrol rate (DCR) and rate of adverse responses between two groups were observed and compared.
Results:ORR and DCR were 27.8% and 83.4% in combination group, and 16.7% and 69.5% in the pemetrexed group,respectively, but there were no significant differences (P>0.05). PFS in combination group and pemetrexedgroup were 4.6 months and 3.9 months respectively (P=0.09), whereas OS in the combination group was 14months, evidently higher than in the pemetrexed group (11 months, P=0.004). Adverse responses in both groupsincluded high blood pressure, bleeding, thrombocytopenia, anemia, elevated transaminase, diarrhea, vomitingand proteinuria, but there were no significant differences (P>0.05).
Conclusions: Bevacizumab concomitantwith pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients withadvanced NSCLC.